within Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BD01_Selegiline;

model Selegiline
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.04,
    Cl = 5.833333333333333e-05,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.16,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0023000000000000004,
    Tlag = 600,
    Vdp = 0.23,
    k12 = 2.0555555555555555e-05,
    k21 = 2.0555555555555555e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Selegiline</td></tr><tr><td>ATC code:</td><td>N04BD01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>160</td><td>L</td></tr>
    <tr><td>clearance:</td><td>210</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Selegiline is a selective, irreversible monoamine oxidase B (MAO-B) inhibitor used primarily as an adjunct in the treatment of Parkinson's disease and sometimes in the treatment of major depressive disorder. It works by increasing dopaminergic activity in the brain. Selegiline is an approved medication widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N04BD01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Selegiline;
